Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours

Trial Profile

TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Vistusertib (Primary) ; Paclitaxel
  • Indications Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms TAX-TORC
  • Most Recent Events

    • 09 Feb 2019 This trial has been completed in United Kingdom.
    • 22 Aug 2018 According to The Institute of Cancer Research media release, this study was funded by AstraZeneca, with support from the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (ICR) and the Experimental Cancer Medicine Centre (ECMC) and part of the Combinations Alliance portfolio.
    • 22 Aug 2018 Results presented in The Institute of Cancer Research media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top